PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer

Nicole Handa, Richard G. Bennett, Eric V. Li, Austin Ho, Mitchell M. Huang, Sai Kumar, Clayton Neill, Ridwan Alam, Hiten D. Patel, Edward M. Schaeffer, Ashley E. RossBJUI 2025 · DOI

TL;DR

This study reveals that PSMA PET/CT scans are highly effective in detecting recurrence in men with high-risk prostate cancer after initial treatment, with nearly 80% showing positive findings. Crucially, these scans identify localized or oligometastatic disease in a significant portion of patients, suggesting they could be candidates for targeted salvage therapies, potentially delaying or avoiding more aggressive systemic treatments.

What Problem Does This Paper Address?

Prostate cancer is a common malignancy, and while initial treatments like radical prostatectomy (RP) and radiation therapy (RT) are often successful, a substantial number of patients experience biochemical recurrence (BCR) – a rise in prostate-specific antigen (PSA) levels – within five years. Historically, managing BCR involved observation or intermittent androgen deprivation therapy (ADT). However, recent advancements in systemic therapies have shown benefits, but these can come with significant side effects. For patients with localized or oligometastatic recurrence, there's a growing interest in less toxic, targeted treatments like salvage local therapies or metastasis-directed therapies. The challenge has been accurately identifying these specific sites of recurrence, especially at low PSA levels, where conventional imaging can be insufficient. This paper addresses this by investigating the utility of PSMA PET/CT, a more sensitive imaging modality, in characterizing the patterns of recurrence in high-risk BCR patients.

Methods

This was a retrospective analysis of 145 patients diagnosed with high-risk BCR after local treatment (RP and/or RT) between July 2021 and March 2023. High-risk BCR was defined by specific PSA thresholds above nadir following RT or RP. Patients were excluded if they had prior chemotherapy, recent ADT, or positive conventional imaging within three months of the PSMA PET/CT scan. The study analyzed the patterns of PSMA PET/CT avidity, categorizing local recurrence (prostate/prostate bed), nodal recurrence (regional lymph nodes), and metastatic recurrence (stratified by the number of lesions and location). Statistical analyses included logistic regression, Pearson's Chi-squared, Wilcoxon rank sum, and Fisher's exact tests to compare patient characteristics and identify associations between treatment strategies and recurrence patterns.

Datasets

The study utilized data from 145 patients who underwent PSMA PET/CT scans at Northwestern University. This dataset is a retrospective collection of clinical and imaging data from patients treated at a single tertiary care center. No new benchmarks were introduced; the study focuses on analyzing existing patient data.

Key Insights and Ideas

  • High Sensitivity of PSMA PET/CT: The study strongly reinforces that PSMA PET/CT is a powerful tool for detecting recurrence in high-risk BCR, identifying disease in a vast majority of patients.
  • Potential for Targeted Therapies: A significant finding is that a substantial proportion of patients (up to 55%) present with localized or oligometastatic disease, making them potential candidates for less toxic, metastasis-directed therapies. This opens doors for personalized treatment strategies.
  • Treatment Strategy Influence: The initial treatment modality (RP, RT, or RP+RT) appears to influence the pattern of recurrence, with RT being associated with higher odds of local recurrence and lower odds of nodal recurrence compared to RP.
  • Oligometastasis Definition: The study highlights that even with a relatively high PSA threshold for inclusion, a notable percentage of patients (40%) with distant metastases had oligometastatic disease (1-3 lesions), further supporting the role of targeted interventions.

Key Results

  • Positive Findings: 77% (113 out of 145) of patients had at least one positive lesion on PSMA PET/CT.
  • Recurrence Patterns:
    • 20% had local recurrence.
  • 21% had nodal recurrence.
  • 37% had distant metastatic recurrence.
  • Metastatic Disease Breakdown: Of those with distant metastases, 40% had oligometastatic disease (1-3 lesions), and 60% had more than 3 lesions.
  • Treatment Impact: Patients who underwent combination RP and RT had a significantly lower risk of a positive PSMA PET/CT compared to RP alone. RT monotherapy was associated with significantly higher odds of local recurrence and lower odds of nodal recurrence compared to RP.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Design: The study's retrospective nature means data availability was not always complete, and some variables (like PSA doubling time) could only be analyzed for a subset of patients.
  • Single Tertiary Center: Data from a single center may not be generalizable to all patient populations.
  • Lack of Histopathological Confirmation: The study did not include histopathological confirmation of PSMA-avid lesions, relying solely on imaging findings.
  • PSA Threshold: The PSA cutoff of >1 ng/ml for patients post-RP is considered relatively high by some, and there's no universal consensus on the optimal PSA threshold for initiating salvage therapies.

Future work should focus on:

  • Evaluating long-term oncologic outcomes and adverse events for patients treated with metastasis-directed therapies based on PSMA PET/CT findings.
  • Further investigating the role of PSMA PET/CT versus conventional imaging in BCR.
  • Determining the optimal timing for systemic therapy initiation and treatment regimens.
  • Exploring the potential benefit of earlier intervention for patients with a higher burden of metastatic disease.

Summary updated

Abstract

Nearly 80% of patients with high-risk BCR after local treatment for prostate cancer with RP and/or RT will have positive findings on PSMA PET/CT. In addition to intensified systemic therapy, up to 55% of the patients may have benefitted from salvage local therapy, nodal pelvic radiation or metastasis-directed therapies for oligometastatic disease.
BibTeX
@inproceedings{handa2025psma,
  author = {Nicole Handa and Richard G. Bennett and Eric V. Li and Austin Ho and Mitchell M. Huang and Sai Kumar and Clayton Neill and Ridwan Alam and Hiten D. Patel and Edward M. Schaeffer and Ashley E. Ross},
  title = {{PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer}},
  booktitle = {BJUI},
  year = {2025},
  doi = {10.1002/bco2.70028},
}
Figure